Recent News

By Category: Agents & Toxins

Elusys Completes Enrollment in Three Phase 3 Safety Studies

(PR Newswire) Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced it has completed enrollment in three phase 3 safety studies of ETI-204, an anti-toxin in development for the treatment of inhalational anthrax. Elusys also announced it has completed enrollment in an additional study to evaluate the tolerability Read More »

February 6, 2014
| Filed under Agents & Toxins and Research
Share

Bioterrorism, Antibiotic-Resistant Bacteria To Be Aided By Carbavance Drug Candidate

(Medical Daily) A new drug may help the U.S. government protect the homeland from a hypothetical bioterrorist threat or something we know is actually trying to kill us: drug-resistant bacteria threatening to undo a century of medical progress.The Department of Health and Human Services on Tuesday announced a five-year public-private partnership with Rempex Pharmaceuticals, of Read More »

February 6, 2014
| Filed under Agents & Toxins and Research
Share

Be alert for anthrax

(Wellington Times) The current dry, hot weather creates conditions favourable for the emergence of anthrax events in those areas that have had a history of the disease in the past. Central West Local Land Services (LLS) is encouraging landholders to look out for sudden deaths in stock and consider vaccinating against this disease where there Read More »

February 5, 2014
| Filed under Asia/Pacific, Agents & Toxins, and Countermeasures
Share

Publishing Data On New Disease Strains Draws Concern Of Intelligence Analysts

(Mint Press News) The new strain produces a type of deadly botulinum toxin for which there is no antidote. For that reason, California scientists and public health officials decided to redact the bacteria’s sequence information to prevent it from falling into terrorist hands.

February 5, 2014
| Filed under North America, Agents & Toxins, Biosafety, and Research
Share

Hawaii Biotech awarded anthrax anti-toxin grant by NIAID

(Pharmaceutical Business Review) The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded Hawaii Biotech a grant to continue the development of anthrax anti-toxin drugs. The small molecule inhibitors under development block anthrax lethal toxin.